Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis

被引：0
作者：
Viola Melone
Annamaria Salvati
Domenico Palumbo
Giorgio Giurato
Giovanni Nassa
Francesca Rizzo
Luigi Palo
Alessandro Giordano
Mariarosaria Incoronato
Mario Vitale
Caterina Mian
Immacolata Di Biase
Stefano Cristiano
Viviana Narciso
Monica Cantile
Annabella Di Mauro
Fabiana Tatangelo
Salvatore Tafuto
Roberta Modica
Claudia Pivonello
Marco Salvatore
Annamaria Colao
Alessandro Weisz
Roberta Tarallo
机构：
[1] University of Salerno,Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”
[2] AOU ‘S. Giovanni di Dio e Ruggi d’Aragona’ University of Salerno,Medical Genomics Program and Division of Oncology
[3] Genome Research Center for Health,Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”
[4] IRCCS Synlab SDN s.p.a,Endocrinology Unit, Department of Medicine (DIMED)
[5] University of Salerno,Pathology Unit
[6] University of Padua,Sarcomas and Rare Tumors Unit
[7] MeriGen Diagnostic & c sas,Department of Clinical Medicine and Surgery, Endocrinology Unit
[8] Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale,undefined
[9] Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale,undefined
[10] Federico II University,undefined
[11] UNESCO Chair for Health Education and Sustainable Development,undefined
[12] Federico II University,undefined
来源：
Journal of Translational Medicine | / 20卷
关键词：
Neuroendocrine neoplasms; Molecular signatures; ATM signaling; Circulating biomarkers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 387 条
[21]  
Bosman FT(2016)Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma J Transl Med 12 473-45
[22]  
Brambilla E(2014)A systematic review of management of neuroendocrine tumors: an experience from a tertiary care centre from India Clin Cancer Invest J 14 707-1161
[23]  
Anlauf M(2021)Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis Ther Adv Endocrinol Metab 39 1-424
[24]  
Garbrecht N(2007)Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study Endocr Relat Cancer 30 32-8
[25]  
Bauersfeld J(2010)The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 47 1149-436
[26]  
Schmitt A(2021)The role of serum 5-HIAA as a predictor of progression and an alternative to 24-h urine 5-HIAA in well-differentiated neuroendocrine neoplasms Biology 16 417-1756
[27]  
Henopp T(2016)Pathologic classification of neuroendocrine neoplasms Hematol Oncol Clin North Am 66 D590-1645
[28]  
Komminoth P(2016)Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus Cancer Treat Rev 34 433-21
[29]  
Ciampi R(2017)The safety of available treatments options for neuroendocrine tumors Expert Opin Drug Saf 49 1747-930
[30]  
Romei C(2019)Therapeutic sequences in patients with grade 1–2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group Endocrine 28 1639-2914
12345678910